Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) was downgraded by stock analysts at Wedbush from an “outperform” rating to a “neutral” rating in a research note issued to investors on Tuesday, Marketbeat.com reports. They presently have a $3.00 price target on the biotechnology company’s stock, down from their prior price target of $8.00. Wedbush‘s target price suggests a potential downside of 14.29% from the company’s previous close.
Several other analysts have also recently issued reports on the company. Craig Hallum set a $9.00 price objective on Aclaris Therapeutics in a research note on Wednesday, October 28th. Wall Street Zen upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 24th. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Aclaris Therapeutics in a research note on Wednesday, October 28th. Canaccord Genuity Group upped their price target on Aclaris Therapeutics from $10.00 to $13.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, September 21st. Three equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Aclaris Therapeutics presently has an average rating of “Buy” and an average price target of $10.67.
Read Our Latest Research Report on Aclaris Therapeutics
Aclaris Therapeutics Price Performance
Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.04. Aclaris Therapeutics had a negative net margin of 1,244.09% and a negative return on equity of 59.19%. The business had revenue of $1.48 million during the quarter, compared to the consensus estimate of $1.27 million. As a group, analysts anticipate that Aclaris Therapeutics will post -0.56 EPS for the current year.
Institutional Trading of Aclaris Therapeutics
Institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp boosted its holdings in shares of Aclaris Therapeutics by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 207,024 shares of the biotechnology company’s stock valued at $776,000 after acquiring an additional 3,507 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Aclaris Therapeutics by 20.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 26,858 shares of the biotechnology company’s stock worth $142,000 after acquiring an additional 4,630 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Aclaris Therapeutics during the third quarter worth approximately $40,000. HighTower Advisors LLC increased its holdings in shares of Aclaris Therapeutics by 3.5% in the 3rd quarter. HighTower Advisors LLC now owns 225,190 shares of the biotechnology company’s stock valued at $1,184,000 after acquiring an additional 7,666 shares during the period. Finally, MBE Wealth Management LLC acquired a new position in shares of Aclaris Therapeutics in the 3rd quarter valued at $53,000. 98.34% of the stock is owned by hedge funds and other institutional investors.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics is a biopharmaceutical company focused on discovering and developing treatments for immuno-inflammatory diseases. Its research programs include small-molecule therapies designed to target pathways involved in inflammation and immune responses. The company’s development portfolio has included candidates for dermatologic and other inflammatory conditions. Aclaris previously developed ESKATA, a topical treatment for raised seborrheic keratoses that received U.S. regulatory approval in 2017.
See Also
- Five stocks we like better than Aclaris Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
